Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared to a placebo in a mid-stage study involving 371 patients.
Ardelyx licensed the drug, tenapanor, to AstraZeneca Plc in October 2012.
The companies are also testing the drug for two kidney-related indications.